SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

BeOne Medicines Wins FDA Priority Review for BRUKINSA Combination

The FDA granted Priority Review to BeOne Medicines' BRUKINSA combination for first-line mantle cell lymphoma.

ONC

Related stories